The Effects of GLP1 Receptor Agonist on Cardiovascular Outcomes in Patients With Type 2 Diabetes

The aim of the study was to evaluate the effects of GLP1 receptor agonist on cardiovascular outcomes in patients with type 2 diabetes treated with or without as GLT2 inhibitors. Most of the near 1000 participants in harmony outcomes as mentioned 6% were treated with agile D2 inhibitors at best line. The effect of albicumatoid on reducing the composite of cardiovascular death, myocardial infection or stroke was consistent with or without GLT2 inhibitor use. In number 2, ameth analysis of harmony outcomes in amplitude O included over 13,000 patients of whom 9% use agility D2 inhibitors. Compared to placebo, GLP1 receptors reduced measured at best cardiovascular events without effect modification